Neuroscience Bulletin

, Volume 29, Issue 2, pp 144–154 | Cite as

Promoting remyelination for the treatment of multiple sclerosis: opportunities and challenges

Review

Abstract

Multiple sclerosis (MS) is a chronic and devastating autoimmune demyelinating disease of the central nervous system. With the increased understanding of the pathophysiology of this disease in the past two decades, many disease-modifying therapies that primarily target adaptive immunity have been shown to prevent exacerbations and new lesions in patients with relapsing-remitting MS. However, these therapies only have limited efficacy on the progression of disability. Increasing evidence has pointed to innate immunity, axonal damage and neuronal loss as important contributors to disease progression. Remyelination of denuded axons is considered an effective way to protect neurons from damage and to restore neuronal function. The identification of several key molecules and pathways controlling the differentiation of oligodendrocyte progenitor cells and myelination has yielded clues for the development of drug candidates that directly target remyelination and neuroprotection. The long-term efficacy of this strategy remains to be evaluated in clinical trials. Here, we provide an overview of current and emerging therapeutic concepts, with a focus on the opportunities and challenges for the remyelination approach to the treatment of MS.

Keywords

multiple sclerosis myelination neurodegeneration oligodendrocytes disease progression disease modifying therapy drug target animal models 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Kuhlmann T, Miron V, Cui Q, Wegner C, Antel J, Brück W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 2008, 131:1749–1758.PubMedCrossRefGoogle Scholar
  2. [2]
    Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 1998, 18:601–609.PubMedGoogle Scholar
  3. [3]
    Chang A, Tourtellotte W, Rudick R, Trapp B. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002, 346:165–173.PubMedCrossRefGoogle Scholar
  4. [4]
    Weiner H. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 2008, 255: 3–11.PubMedCrossRefGoogle Scholar
  5. [5]
    Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals Neurol 2000, 47: 707–717.CrossRefGoogle Scholar
  6. [6]
    Xiao L, Guo D, Hu C, Shen W, Shan L, Li C, et al. Diosgenin promotes oligodendrocyte progenitor cell differentiation through estrogen receptor-mediated ERK1/2 activation to accelerate remyelination. Glia 2012, 60: 1037–1052.PubMedCrossRefGoogle Scholar
  7. [7]
    Silvestroff L, Bartucci S, Pasquini J, Franco P. Cuprizoneinduced demyelination in the rat cerebral cortex and thyroid hormone effects on cortical remyelination. Exp Neurol 2012, 235: 357–367.PubMedCrossRefGoogle Scholar
  8. [8]
    Franco P, Silvestroff L, Soto E, Pasquini J. Thyroid hormones promote differentiation of oligodendrocyte progenitor cells and improve remyelination after cuprizone-induced demyelination. Exp Neurol 2008, 212: 458–467.PubMedCrossRefGoogle Scholar
  9. [9]
    Raff M, Lillien L, Richardson W, Burne J, Noble M. Platelet derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature 1988, 333: 562–565.PubMedCrossRefGoogle Scholar
  10. [10]
    Watkins T, Emery B, Mulinyawe S, Barres B. Distinct stages of myelination regulated by gamma-secretase and astrocytes in a rapidly myelinating CNS coculture system. Neuron 2008, 60: 555–569.PubMedCrossRefGoogle Scholar
  11. [11]
    Jeffery N, Blakemore W. Remyelination of mouse spinal cord axons demyelinated by local injection of lysolecithin. J Neurocytol 1995, 24: 775–781.PubMedCrossRefGoogle Scholar
  12. [12]
    Matsushima G, Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001, 11: 107–116.PubMedCrossRefGoogle Scholar
  13. [13]
    Kirby BB, Takada N, Latimer AJ, Shin J, Carney TJ, Kelsh RN, et al. In vivo time-lapse imaging shows dynamic oligodendrocyte progenitor behavior during zebrafish development. Nat Neurosci 2006, 9: 1506–1511.PubMedCrossRefGoogle Scholar
  14. [14]
    Lyons DA, Naylor SG, Scholze A, Talbot WS. Kif1b is essential for mRNA localization in oligodendrocytes and development of myelinated axons. Nat Genet 2009, 41: 854–858.PubMedCrossRefGoogle Scholar
  15. [15]
    Harsan L, Steibel J, Zaremba A, Agin A, Sapin R, Poulet P, et al. Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J Neurosci 2008, 28: 14189–14201.PubMedCrossRefGoogle Scholar
  16. [16]
    Kondo T, Raff M. Basic helix-loop-helix proteins and the timing of oligodendrocyte differentiation. Development 2000, 127: 2989–2998.PubMedGoogle Scholar
  17. [17]
    Lu Q, Sun T, Zhu Z, Ma N, Garcia M, Stiles C, et al. Common developmental requirement for olig function indicates a motor neuron/oligodendrocyte connection. Cell 2002, 109: 75–86.PubMedCrossRefGoogle Scholar
  18. [18]
    Lu QR, Park JK, Noll E, Chan JA, Alberta J, Yuk D, et al. oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A 2001, 98: 10851–10856.PubMedCrossRefGoogle Scholar
  19. [19]
    Qi Y, Cai J, Wu Y, Wu R, Lee J, Fu H, et al. Control of oligodendrocyte differentiation by the Nkx2.2 homeodomain transcription factor. Development 2001, 128: 2723–2733.PubMedGoogle Scholar
  20. [20]
    Zhou Q, Wang S, Anderson DJ. Identification of a novel family of oligodendrocyte lineage-specific basic helix-loop-helix transcription factors. Neuron 2000, 25: 331–343.PubMedCrossRefGoogle Scholar
  21. [21]
    He Y, Dupree J, Wang J, Sandoval J, Li J, Liu H, et al. The transcription factor Yin Yang 1 is essential for oligodendrocyte progenitor differentiation. Neuron 2007, 55: 217–230.PubMedCrossRefGoogle Scholar
  22. [22]
    Finzsch M, Stolt CC, Lommes P, Wegner M. Sox9 and Sox10 influence survival and migration of oligodendrocyte precursors in the spinal cord by regulating PDGF receptor alpha expression. Development 2008, 135: 637–646.PubMedCrossRefGoogle Scholar
  23. [23]
    Wang S, Dulin J, Wu H, Hurlock E, Lee S, Jansson K, et al. An oligodendrocyte-specific zinc-finger transcription regulator cooperates with olig2 to promote oligodendrocyte differentiation. Development 2006, 133: 3389–3398.PubMedCrossRefGoogle Scholar
  24. [24]
    Emery B, Agalliu D, Cahoy JD, Watkins TA, Dugas JC, Mulinyawe SB, et al. Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination. Cell 2009, 138: 172–185.PubMedCrossRefGoogle Scholar
  25. [25]
    Shen YH, Avila RL, Emery B, Traka M, Lin W, Watkins T, et al. Zfp191 is required by oligodendrocytes for CNS myelination. Genes Dev 2010, 24: 301–311.CrossRefGoogle Scholar
  26. [26]
    Chen Y, Wu H, Wang S, Koito H, Li J, Ye F, et al. The oligodendrocyte-specific G protein-coupled receptor Gpr17 is a cell-intrinsic timer of myelination. Nat Neurosci 2009, 12: 1398–1406.PubMedCrossRefGoogle Scholar
  27. [27]
    Koenning M, Jackson S, Hay CM, Faux C, Kilpatrick TJ, Willingham M, et al. Myelin gene regulatory factor is required for maintenance of myelin and mature oligodendrocyte identity in the adult CNS. J Neurosci 2012, 32: 12528–12542.PubMedCrossRefGoogle Scholar
  28. [28]
    Huang J, Jarjour A, Oumesmar B, Kerninon C, Williams A, Krezel W, et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci 2011, 14: 45–55.PubMedCrossRefGoogle Scholar
  29. [29]
    Xin M, Yue T, Ma Z, Wu FF, Gow A, Lu QR. Myelinogenesis and axonal recognition by oligodendrocytes in brain are uncoupled in olig1-null mice. J Neurosci 2005, 25: 1354–1365.PubMedCrossRefGoogle Scholar
  30. [30]
    Lecca D, Trincavelli ML, Gelosa P, Sironi L, Ciana P, Fumagalli M, et al. The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One 2008, 3: 1–15.CrossRefGoogle Scholar
  31. [31]
    Fumagalli M, Daniele S, Lecca D, Lee P, Parravicini C, Fields R, et al. Phenotypic changes, signaling pathway, and functional correlates of GPR17-expressing neural precursor cells during oligodendrocyte differentiation. J Biol Chem 2011, 286: 10593–10604.PubMedCrossRefGoogle Scholar
  32. [32]
    Ceruti S, Viganò F, Boda E, Ferrario S, Magni G, Boccazzi M, et al. Expression of the new P2Y-like receptor GPR17 during oligodendrocyte precursor cell maturation regulates sensitivity to ATP-induced death. Glia 2011, 59: 363–378.PubMedCrossRefGoogle Scholar
  33. [33]
    Wang S, Sdrulla AD, diSibio G, Bush G, Nofziger D, Hicks C, et al. Notch receptor activation inhibits oligodendrocyte differentiation. Neuron 1998, 21: 63–75.PubMedCrossRefGoogle Scholar
  34. [34]
    Hu QD, Ang BT, Karsak M, Hu WP, Cui XY, Duka T, et al. F3/ contactin acts as a functional ligand for Notch during oligodendrocyte maturation. Cell 2003, 115: 163–175.PubMedCrossRefGoogle Scholar
  35. [35]
    John G, Shanker S, Shafit-Zagardo B, Massimi A, Lee SC, Raine CS, et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 2002, 8: 1115–1121.PubMedCrossRefGoogle Scholar
  36. [36]
    Zhang Y, Argaw AT, Gurfein BT, Zameer A, Snyder BJ, Ge C, et al. Notch1 signaling plays a role in regulating precursor differentiation during CNS remyelination. Proc Natl Acad Sci U S A 2009, 106: 19162–19167.PubMedCrossRefGoogle Scholar
  37. [37]
    Stidworthy MF, Genoud S, Li WW, Leone DP, Mantei N, Suter U, et al. Notch1 and Jagged1 are expressed after CNS demyelination, but are not a major rate-determining factor during remyelination. Brain 2004, 127: 1928–1941.PubMedCrossRefGoogle Scholar
  38. [38]
    Fancy SP, Baranzini SE, Zhao C, Yuk DI, Irvine KA, Kaing S, et al. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev 2009, 23: 1571–1585.PubMedCrossRefGoogle Scholar
  39. [39]
    Ye F, Chen Y, Hoang T, Montgomery R, Zhao X, Bu H, et al. HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting β-Catenin-TCF interaction. Nat Neurosci 2009, 12: 829–838.PubMedCrossRefGoogle Scholar
  40. [40]
    Fancy S, Harrington E, Yuen T, Silbereis J, Zhao C, Baranzini S, et al. Axin2 as regulatory and therapeutic target in new born brain injury and remyelination. Nat Neurosci 2011, 14: 1009–1016.PubMedCrossRefGoogle Scholar
  41. [41]
    Gross R, Mehler M, Mabie P, Zang Z, Santschi L, Kessler J. Bone morphogenetic proteins promote astroglial lineage commitment by mammalian subventricular zone progenitor cells. Neuron 1996, 17: 595–606.PubMedCrossRefGoogle Scholar
  42. [42]
    Samanta J, Kessler J. Interactions between ID and OLIG proteins mediate the inhibitory effects of BMP4 on oligodendroglial differentiation. Development 2004, 131: 4131–4142.PubMedCrossRefGoogle Scholar
  43. [43]
    Sabo J, Aumann T, Merlo D, Kilpatrick T, Cate H. Remyelination is altered by bone morphogenic protein signaling in demyelinated lesions. J Neurosci 2011, 31: 4504–4510.PubMedCrossRefGoogle Scholar
  44. [44]
    Cate H, Sabo J, Merlo D, Kemper D, Aumann T, Robinson J, et al. Modulation of bone morphogenic protein signalling alters numbers of astrocytes and oligodendroglia in the subventricular zone during cuprizone-induced demyelination. J Neurochem 2010, 115: 11–22.PubMedCrossRefGoogle Scholar
  45. [45]
    Wu M, Hernandez M, Shen S, Sabo JK, Kelkar D, Wang J, et al. Differential modulation of the oligodendrocyte transcriptome by sonic hedgehog and bone morphogenetic protein 4 via opposing effects on histone acetylation. J Neurosci 2012, 32: 6651–6664.PubMedCrossRefGoogle Scholar
  46. [46]
    Cheng X, Wang Y, He Q, Qiu M, Whittemore SR, Cao Q. Bone morphogenetic protein signaling and olig1/2 interact to regulate the differentiation and maturation of adult oligodendrocyte precursor cells. Stem Cells 2007, 25: 3204–3214.PubMedCrossRefGoogle Scholar
  47. [47]
    Mi S, Lee X, Shao Z, Thill G, Ji B, Relton J, et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci 2004, 7: 221–228.PubMedCrossRefGoogle Scholar
  48. [48]
    Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 2005, 8: 745–751.PubMedCrossRefGoogle Scholar
  49. [49]
    Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, Yuan Q, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 2007, 10: 1228–1233.CrossRefGoogle Scholar
  50. [50]
    Lee X, Yang Z, Shao Z, Rosenberg SS, Levesque M, Pepinsky RB, et al. NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J Neurosci 2007, 27: 220–225.PubMedCrossRefGoogle Scholar
  51. [51]
    Zhao XH, Jin WL, Ju G. An in vitro study on the involvement of LINGO-1 and Rho GTPases in Nogo-A regulated differentiation of oligodendrocyte precursor cells. Mol Cell Neurosci 2007, 36: 260–269.PubMedCrossRefGoogle Scholar
  52. [52]
    Mi S, Miller R, Tang W, Lee X, Hu B, Wu W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Annals Neurol 2009, 65: 304–315.CrossRefGoogle Scholar
  53. [53]
    Satoh J, Tabunoki H, Yamamura T, Arima K, Konno H. TROY and LINGO-1 expression in astrocytes and macrophages/ microglia in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2007, 33: 99–107.PubMedCrossRefGoogle Scholar
  54. [54]
    Maness P, Schachner M. Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat Neurosci 2007, 10: 19–27.PubMedCrossRefGoogle Scholar
  55. [55]
    Trotter J, Bitter-Suermann D, Schachner M. Differentiation-regulated loss of the polysialylated embryonic form and expression of the different polypeptides of the neural cell adhesion molecule by cultured oligodendrocytes and myelin. J Neurosci Res 1989, 22: 369–383.PubMedCrossRefGoogle Scholar
  56. [56]
    Seki T, Arai Y. Expression of highly polysialylated NCAM in the neocortex and piriform cortex of the developing and the adult rat. Anat Embryol (Berl) 1991, 184: 395–401.CrossRefGoogle Scholar
  57. [57]
    Seki T, Arai Y. Distribution and possible roles of the highly polysialylated neural cell adhesion molecule (NCAM-H) in the developing and adult central nervous system. Neurosci Res 1993, 17: 265–290.PubMedCrossRefGoogle Scholar
  58. [58]
    Oumesmar BN, Vignais L, Duhamel-Clerin E, Avellana-Adalid V, Rougon G, Baron-Van Evercooren A. Expression of the highly polysialylated neural cell adhesion molecule during postnatal myelination and following chemically induced demyelination of the adult mouse spinal cord. Eur J Neurosci 1995, 7: 480–491.CrossRefGoogle Scholar
  59. [59]
    Charles P, Hernandez MP, Stankoff B, Aigrot MS, Colin C, Rougon G, et al. Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule. Proc Natl Acad Sci U S A 2000, 97: 7585–7590.PubMedCrossRefGoogle Scholar
  60. [60]
    Fewou SN, Ramakrishnan H, Bussow H, Gieselmann V, Eckhardt M. Down-regulation of polysialic acid is required for efficient myelin formation. J Biol Chem 2007, 282: 16700–16711.PubMedCrossRefGoogle Scholar
  61. [61]
    Charles P, Reynolds R, Seilhean D, Rougon G, Aigrot MS, Niezgoda A, et al. Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis? Brain 2002, 125:1972–1979.PubMedCrossRefGoogle Scholar
  62. [62]
    Laursen L, Chan C, Ffrench-Constant C. An integrin-contactin complex regulates CNS myelination by differential Fyn phosphorylation. J Neurosci 2009, 29: 9174–9185.PubMedCrossRefGoogle Scholar
  63. [63]
    White R, Gonsior C, Krämer-Albers E, Stöhr N, Hüttelmaier S, Trotter J. Activation of oligodendroglial Fyn kinase enhances translation of mRNAs transported in hnRNP A2-dependent RNA granules. J Cell Biol 2009, 181: 579–586.CrossRefGoogle Scholar
  64. [64]
    Kubasak MD, Hedlund E, Roy RR, Carpenter EM, Edgerton VR, Phelps PE. L1 CAM expression is increased surrounding the lesion site in rats with complete spinal cord transection as neonates. Exp Neurol 2005, 194(2): 363–375.PubMedCrossRefGoogle Scholar
  65. [65]
    Martini R, Schachner M. immunoelectron microscopic localization of neural cell adhesion molecules (L1, N-CAM, and myelin-associated glycoprotein) in regenerating adult mouse sciatic nerve. J Cell Biol 1988, 106: 1735–1746.PubMedCrossRefGoogle Scholar
  66. [66]
    Roonprapunt C, Huang W, Grill R, Friedlander D, Grumet M, Chen S, et al. Soluble cell adhesion molecule L1-Fc promotes locomotor recovery in rats after spinal cord injury. J Neurotrauma 2003, 20: 871–882.PubMedCrossRefGoogle Scholar
  67. [67]
    Xu G, Nie DY, Wang WZ, Zhang PH, Shen J, Ang BT, et al. optic nerve regeneration in polyglycolic acid-chitosan conduits coated with recombinant L1-Fc. Neuroreport 2004, 15: 2167–2172.PubMedCrossRefGoogle Scholar
  68. [68]
    Zhang Y, Bo X, Schoepfer R, Holtmaat AJ, Verhaagen J, Emson PC, et al. Growth-associated protein GAP-43 and L1 act synergistically to promote regenerative growth of Purkinje cell axons in vivo. Proc Natl Acad Sci U S A 2005, 102: 14883–14888.PubMedCrossRefGoogle Scholar
  69. [69]
    Schmidt F, Eijnden M, Gobert R, Saborio G, Carboni S, Alliod C, et al. Identification of VHY/Dusp15 as a regulator of oligodendrocyte differentiation through a systematic genomics approach. PLoS One 2012, 7: e40457.PubMedCrossRefGoogle Scholar
  70. [70]
    Bernard F, Moreau-Fauvarque C, Heitz-Marchaland C, Zagar Y, Dumas L, Fouquet S, et al. Role of transmembrane semaphorin Sema6A in oligodendrocyte differentiation and myelination. Glia 2012, 60: 1590–604.PubMedCrossRefGoogle Scholar
  71. [71]
    Fancy S, Glasgow S, Finley M, Rowitch D, Deneen B. Evidence that nuclear factor IA inhibits repair after white matter injury. Annals Neurol 2012, 72: 224–233.CrossRefGoogle Scholar
  72. [72]
    Kuboyama K, Fujikawa A, Masumura M, Suzuki R, Matsumoto M, Noda M. Protein tyrosine phosphatase receptor type z negatively regulates oligodendrocyte differentiation and myelination. PLoS One 2012, 7: e48797.PubMedCrossRefGoogle Scholar
  73. [73]
    Bö L, Vedeler CA, Nyland HI, Trapp BD, Mök SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003, 62: 723–732.PubMedGoogle Scholar
  74. [74]
    Peterson JW, Bö L, Mök S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001, 50: 389–400.PubMedCrossRefGoogle Scholar
  75. [75]
    Kutzelnigg A, Lucchinetti CF, Stadekmann C, Brück W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128: 2705–2712.PubMedCrossRefGoogle Scholar
  76. [76]
    Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011, 365: 2188–2197.PubMedCrossRefGoogle Scholar
  77. [77]
    Howell O, Reeves C, Nicholas R, Carassiti D, Radotra B, Gentleman S, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011, 134: 2755–2771.PubMedCrossRefGoogle Scholar
  78. [78]
    Victora GD, Nussenzweig MC. Germinal centers. Annu Rev immunol 2012, 30: 429–457.PubMedCrossRefGoogle Scholar
  79. [79]
    Han M, Huwang S, Roy D, Lundgren D, Price J, Ousman S, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008, 451: 1076–1081.PubMedCrossRefGoogle Scholar
  80. [80]
    MacKay A, Whittall K, Adler J, Li D, Paty D, Graeb D. In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med 1994, 31: 673–677.PubMedCrossRefGoogle Scholar
  81. [81]
    Narayanan S, Francis SJ, Sled JG, Santos AC, Antel S, Levesque I, et al. Axonal injury in the cerebral normalappearing white matter of patients with multiple sclerosis is related to concurrent demyelination in lesions but not to concurrent demyelination in normal-appearing white matter. Neuroimage 2006, 29: 637–642.PubMedCrossRefGoogle Scholar
  82. [82]
    Stankoff B, Freeman L, Aigrot MS, Chardain A, Dolle F, Williams A, et al. imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-(1)(1)C]-2-(4′-methylaminophenyl)-6-hydroxybenzothiazole. Ann Neurol 2011, 69: 673–680.PubMedCrossRefGoogle Scholar
  83. [83]
    Stankoff B, Wang Y, Bottlaender M, Aigrot MS, Dolle F, Wu C, et al. Imaging of CNS myelin by positron-emission tomography. Proc Natl Acad Sci U S A 2006, 103: 9304–9309.PubMedCrossRefGoogle Scholar
  84. [84]
    Joubert L, Foucault I, Sagot Y, Bernasconi L, Duval F, Alliod C, et al. Chemical inducers and transcriptional markers of oligodendrocyte differentiation. J Neurosci Res 2010, 88: 2546–2557.PubMedGoogle Scholar
  85. [85]
    Taupin P. Thirteen compounds promoting oligodendrocyte progenitor cell differentiation and remyelination for treating multiple sclerosis: WO2010054307. Expert Opin Ther Pat 2010, 20: 1767–1773.PubMedCrossRefGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Neuroimmunology Discovery Performance UnitGlaxoSmithKline Research and Development CenterShanghaiChina
  2. 2.Altimab Therapeutics, Inc.LafayetteUSA

Personalised recommendations